Biology subjects

Thommis, J.

Publications and source records attributed to Thommis, J..

5 recordsLinked to original sources

bioRxiv2024

PPARalpha-ERRalpha crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression

Background and aimsMetabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common liver disease worldwide. This study investigates how targeting two key nuclear receptors involved in hepatic energy metabolism, peroxisome proliferator-activated receptor alpha (PPAR) and estrogen-related receptor alpha (ERR), impacts MASLD. MethodsThe PPAR agonist pemafibrate and/or ERR inverse agonist C29 were administered in a short- and long-term Western diet plus fructose model, and a diabetic-background streptozotocin-Western diet model (STZ-WD). Liver morphology, histological samples, serum metabolites, RNA and protein levels were analysed and scanning electron microscopy was performed. In addition, we performed cell-based assays and immunohistochemistry and immunofluorescence stainings with light and super-resolution confocal microscopy of healthy, MASLD and MASH human livers. ResultsThe ligand combinations efficacy was underscored by reduced liver steatosis in all the mouse models. Both long-term models showed improvements in body weight and liver morphology, alongside reductions in inflammation and fibrosis. Additionally, tumor formation was prevented in the STZ-WD mice model. Cell-based assays demonstrated that ERR inhibits PPARs activity, likely explaining why ERR blockage improves inflammatory and lipid metabolism gene profiles and enhances lipid-lowering effects. Complementary RNA sequencing and shotgun proteomics, combined with enrichment analysis, jointly identified downregulated serum amyloid A1/A2 as an essential component underlying the combination treatments effectiveness. MASLD/MASH patient livers showed reduced PPAR and increased ERR levels supporting disrupted NR crosstalk in the hepatocyte nucleus. ConclusionOur study comprehensively supports that dual nuclear receptor targeting by simultaneously increasing PPAR and diminishing ERR activity may represent a viable novel strategy against MASLD. Lay summaryOur study using three distinct MASLD mouse models shows that a simultaneous targeting of PPAR and ERR reduces liver fat, fibrosis, inflammation, and tumor formation. The combination treatment modifies lipid metabolism pathways, and uniquely lowers levels of serum amyloid A1/A2 in the liver. Impact and implicationsOur research introduces a novel therapeutic strategy against MASLD by simultaneously increasing PPAR activity while diminishing ERR activity. With PPAR agonists already tested in phase III clinical trials, ERR ligands/modulators need further (clinical) development to make our findings applicable to both MASLD patients and physicians.

pharmacology and toxicology↗

bioRxiv2024

Crosstalk interactions between transcription factors ERRalpha and PPARalpha assist PPARalpha-mediated gene expression

The peroxisome proliferator-activated receptor (PPAR) is a crucial transcription factor governing genes associated with fatty acid {beta}-oxidation. How various interacting proteins modulate PPARs transcriptional function remains incompletely understood. Employing an unbiased mammalian protein-protein interaction trap with liganded PPAR as bait, we identified an interaction with the orphan nuclear receptor estrogen-related receptor (ERR). Random mutagenesis scanning of PPARs ligand-binding domain and coregulator profiling experiments implicated bridging coregulators, while in vitro studies suggested a trimeric interaction involving RXR. The PPAR{middle dot}ERR interaction, dependent on three C-terminal residues within ERRs helix 12, was reinforced by PGC1 and serum deprivation. Pharmacological inhibition of ERR reduced its interaction with ligand-activated PPAR, revealing a transcriptome indicative of ERR functioning as a transcriptional repressor on prototypical PPAR target genes. Intriguingly, ERR exhibited opposite behavior on other PPAR targets, including the isolated PDK4 enhancer. Chromatin immunoprecipitation analyses demonstrated PPAR ligand-dependent recruitment of ERR onto specific chromatin regions where PPAR binds in mouse livers. These findings highlight intricate transcriptional crosstalk mechanisms between PPAR and ERR, suggesting a multi-layered regulatory network fine-tuning PPARs activity as a nutrient-sensing transcription factor.

molecular biology↗

bioRxiv2023

Antagonism and selective modulation of the human glucocorticoid receptor both reduce recruitment of p300/CBP and the Mediator complex

Exogenous glucocorticoids are frequently used to treat inflammatory disorders and as adjuncts for treatment of solid cancers. However, their use is associated with severe side effects and therapy resistance. Novel glucocorticoid receptor (GR) ligands with a patient-validated reduced side effect profile have not yet reached the clinic. GR is a member of the nuclear receptor family of transcription factors and heavily relies on interactions with coregulator proteins for its transcriptional activity. To elucidate the role of the GR interactome in the differential transcriptional activity of GR following treatment with agonists, antagonists, or lead selective GR agonists and modulators (SEGRAMs), we generated comprehensive interactome maps by high-confidence proximity proteomics in lung epithelial carcinoma cells. We found that the GR antagonist RU486 and the SEGRAM Dagrocorat both reduced GR interaction with CREB-binding protein (CBP)/p300 and the Mediator complex when compared to the full GR agonist Dexamethasone. Our data offer new insights into the role of differential coregulator recruitment in shaping ligand-specific GR-mediated transcriptional responses. In BriefGlucocorticoids are commonly prescribed for the treatment of inflammatory disorders but are associated with severe side effects. Novel glucocorticoid receptor (GR) ligands with strong anti-inflammatory effects but reduced side effects are still sought after. Despite decades-long GR research, there is still an incomplete understanding of the molecular mechanisms driving context-specific GR activity. Using proximity labeling proteomics, we identified CREB-binding protein (CBP), p300 and the Mediator complex as potential crucial GR coregulators driving ligand-induced changes in GRs transcriptional activity. HighlightsO_LIGlucocorticoids (GCs), potent anti-inflammatory agents, can elicit side effects C_LIO_LIMore selective GCs, causing less side effects, are currently still unavailable C_LIO_LILack of fundamental insights on context-specific actions of the GC receptor (GR) C_LIO_LIWe mapped ligand-specific GR interactomes using proximity labeling proteomics C_LIO_LIp300/CBP and Mediator undergo ligand-dependent changes in interaction with GR C_LI

molecular biology↗

bioRxiv2023

Crosstalk between the glucocorticoid and mineralocorticoid receptor boosts glucocorticoid-induced killing of multiple myeloma cells

The glucocorticoid receptor (GR) is a crucial drug target in multiple myeloma as its activation with glucocorticoids effectively triggers myeloma cell death. However, as high-dose glucocorticoids are also associated with deleterious side effects, novel approaches are urgently needed to improve GR action in myeloma. Here we reveal a functional crosstalk between GR and the mineralocorticoid receptor (MR) that culminates in improved myeloma cell killing. We show that the GR agonist Dexamethasone (Dex) downregulates MR levels in a GR-dependent way in myeloma cells. Co-treatment of Dex with the MR antagonist Spironolactone (Spi) enhances Dex-induced cell killing in primary, newly diagnosed GC-sensitive myeloma cells. In a relapsed GC-resistant setting, Spi alone induces distinct myeloma cell killing. On a mechanistic level, we find that a GR-MR crosstalk likely arises from an endogenous interaction between GR and MR in myeloma cells. Quantitative dimerization assays show that Spi reduces Dex-induced GR-MR heterodimerization and completely abolishes Dex-induced MR-MR homodimerization, while leaving GR-GR homodimerization intact. Unbiased transcriptomics analyses reveal that c-myc and many of its target genes are downregulated most by combined Dex-Spi treatment. Proteomics analyses further identify that several metabolic hallmarks are modulated most by this combination treatment. Finally, we identified a subset of Dex-Spi downregulated genes and proteins that may predict prognosis in the CoMMpass myeloma patient cohort. Our study demonstrates that GR-MR crosstalk is therapeutically relevant in myeloma as it provides novel strategies for glucocorticoid-based dose-reduction.

cancer biology↗

bioRxiv2022

Novel assays monitoring direct glucocorticoid receptor protein activity exhibit high predictive power for ligand activity on endogenous gene targets

Exogenous glucocorticoids are widely used in the clinic for the treatment of inflammatory disorders and auto-immune diseases. Unfortunately, their use is hampered by many side effects and therapy resistance. Efforts to find more selective glucocorticoid receptor (GR) agonists and modulators (called SEGRAMs) that are able to separate anti-inflammatory effects via gene repression from metabolic effects via gene activation, have been unsuccessful so far. In this study, we characterized a set of functionally diverse GR ligands in A549 cells, first using a panel of luciferase-based reporter gene assays evaluating GR-driven gene activation and gene repression. We expanded this minimal assay set with novel luciferase-based read-outs monitoring GR protein levels, GR dimerization and GR Serine 211 (Ser211) phosphorylation status and compared their outcomes with compound effects on the mRNA levels of known GR target genes in A549 cells and primary hepatocytes. We found that luciferase reporters evaluating GR-driven gene activation and gene repression were not always reliable predictors for effects on endogenous target genes. Remarkably, our novel assay monitoring GR Ser211 phosphorylation levels proved to be the most reliable predictor for compound effects on almost all tested endogenous GR targets, both driven by gene activation and repression. The integration of this novel assay in existing screening platforms running both in academia and industry may therefore boost chances to find novel GR ligands with an actual improved therapeutic benefit.

pharmacology and toxicology↗